Department of Oncology, The Affiliated Hospital of Southwest Medical University, 646000, Luzhou, PR China.
Department of Oncology, The People's Hospital of Luzhou, 646000, Luzhou, PR China.
Epigenomics. 2024;16(14):999-1012. doi: 10.1080/17501911.2024.2388017. Epub 2024 Aug 28.
To explore the LTBP4's expression, prognostic significance and molecular mechanism of action in breast cancer (BC). On the basis of omics datasets and experiments, we conducted a synthetical analysis of LTBP4 in BC. LTBP4 was downregulated in BC with high promoter methylation and low genetic alteration. DNA methylation was negatively associated with LTBP4 mRNA expression. Higher LTBP4 associated with better survival. LTBP4 was enrichment in extracellular matrix receptor interactions, cell adhesion molecules, cell cycle and MAPK pathway. LTBP4 expression and methylation were positively and negatively associated with tumor infiltrating immune cells, respectively. In conclusion, LTBP4 is a putative tumor suppressor in BC, which expression is regulated by DNA methylation and relates with prognosis.
探讨 LTBP4 在乳腺癌(BC)中的表达、预后意义和作用机制。基于组学数据集和实验,我们对 LTBP4 在 BC 中的作用进行了综合分析。LTBP4 在 BC 中表达下调,启动子甲基化水平高,遗传改变低。DNA 甲基化与 LTBP4 mRNA 表达呈负相关。较高的 LTBP4 与更好的生存相关。LTBP4 富集在细胞外基质受体相互作用、细胞黏附分子、细胞周期和 MAPK 通路中。LTBP4 的表达和甲基化分别与肿瘤浸润免疫细胞呈正相关和负相关。总之,LTBP4 是 BC 中的一个潜在肿瘤抑制因子,其表达受 DNA 甲基化调控,与预后相关。